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Angiotensin II type 1 receptor (AT1R) is a G protein-
coupled receptor that serves as a primary regulator
for blood pressure maintenance. Although several
anti-hypertensive drugs have been developed as
AT1R blockers (ARBs), the structural basis for AT1R
ligand-binding and regulation has remained elusive,
mostly due to the difficulties of growing high-quality
crystals for structure determination using synchro-
tron radiation. By applying the recently developed
method of serial femtosecond crystallography at an
X-ray free-electron laser, we successfully deter-
mined the room-temperature crystal structure of
the human AT1R in complex with its selective antag-
onist ZD7155 at 2.9-A˚ resolution. The AT1R-ZD7155
complex structure revealed key structural features
of AT1R and critical interactions for ZD7155 binding.
Docking simulations of the clinically used ARBs into
the AT1R structure further elucidated both the
common and distinct binding modes for these anti-
hypertensive drugs. Our results thereby provide
fundamental insights into AT1R structure-function
relationship and structure-based drug design.
INTRODUCTION
Cardiovascular disease remains one of the main causes of death
throughout the world despite impressive advances in diagnosisand therapeutics during the past few decades. Hypertension is
the most common modifiable risk factor in cardiovascular dis-
ease, as myocardial infarction, stroke, heart failure, and renal
disease can be greatly reduced by lowering blood pressure (Za-
man et al., 2002). The best known regulator of blood pressure is
the renin-angiotensin system (RAS). Over-stimulation of the RAS
is implicated in hypertension, cardiac hypertrophy, heart failure,
ischemic heart disease, and nephropathy (Balakumar and Jaga-
deesh, 2014). A cascade of proteolytic reactions in the RAS can
generate various angiotensin peptides. Renin cleaves the pre-
cursor protein, angiotensinogen, releasing the inactive angio-
tensin I. Subsequently, angiotensin I is cleaved by angiotensin
converting enzyme (ACE) to generate angiotensin II (AngII),
angiotensin III, and angiotensin 1-7. These peptides exert
diverse functions; angiotensins II and III act as vasoconstrictors,
while angiotensin 1-7 acts as a vasodilator (Zaman et al., 2002).
AngII is also responsible for cell migration, protein synthesis,
endothelial dysfunction, inflammation, and fibrosis (Ramchan-
dran et al., 2006).
In humans, AngII binds to two subtypes of angiotensin G pro-
tein-coupled receptors (GPCRs), angiotensin II type 1 receptor
(AT1R) and angiotensin II type 2 receptor (AT2R) (Oliveira et al.,
2007). Almost all physiological and pathophysiological effects
of AngII are mediated by AT1R (de Gasparo et al., 2000), while
the function of AT2R remains largely unknown (Akazawa et al.,
2013). AT1R exhibits multiple active conformations, thereby acti-
vating different signaling pathways with differential functional
outcomes (Shenoy and Lefkowitz, 2005). The G protein-depen-
dent signaling by AT1R is vital for normal cardiovascular homeo-
stasis yet detrimental in chronic dysfunction, which associates
with cell death and tissue fibrosis and leads to cardiacCell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc. 833
hypertrophy and heart failure (Ma et al., 2010). Accumulating
evidence suggests that G protein independent b-arrestin medi-
ated signaling by AT1R confers cardio-protective benefits
(Whalen et al., 2011; Wisler et al., 2014).
Targeting the RAS cascade has proven to be effective in the
treatment of hypertension, as well as specific cardiovascular
and renal disorders. The most commonly used drugs include
renin inhibitors, ACE inhibitors, and AT1R blockers (ARBs).
ARBs, or sartans, are non-peptide antagonists and include the
well-known anti-hypertensive drugs losartan, candesartan,
valsartan, irbesartan, telmisartan, eprosartan, olmesartan, and
azilsartan, most of which share a common biphenyl-tetrazole
scaffold (Burnier and Brunner, 2000; Imaizumi et al., 2013; Miura
et al., 2013a; Miura et al., 2013b). These ARBs are now exten-
sively used for the treatment of cardiovascular diseases,
including hypertension, cardiac hypertrophy, arrhythmia, and
heart failure. There is additional interest in ARBs regarding their
efficacy in the treatment of blood-vessel diseases such as Mar-
fan-like syndrome, aortic dissection, and aortic aneurysms
(Keane and Pyeritz, 2008; Ramanath et al., 2009).
Previous functional studies on AT1R have provided numerous
clues into AT1R activation and inhibition mechanisms (Oliveira
et al., 2007). Despite its high medical relevance and decades
of research, the structure of AT1R and the binding mode of
ARBs, however, are still unknown, which limits our understand-
ing of the structural basis for AT1R function and modulation
and precludes the rational optimization of AT1R lead com-
pounds. One such experimental anti-hypertensive compound
is ZD7155, a high-affinity antagonist and precursor to the anti-
hypertensive drug candesartan. ZD7155 has a biphenyl-tetra-
zole scaffold similar to other ARBs and is more potent and
longer-lasting than the first clinically used ARB losartan (Jungg-
ren et al., 1996). While structures of several different GPCRs
have been reported, the determination of a new GPCR structure
remains a significant challenge. X-ray crystallography using syn-
chrotron radiation requires sufficiently large crystals in order to
collect high-resolution data. Our extensive efforts to solve the
AT1R structure were hampered by the limited size of micro-crys-
tals grown in the membrane mimetic matrix known as lipidic cu-
bic phase (LCP) (Caffrey and Cherezov, 2009). Nevertheless, by
applying the recently developed method of serial femtosecond
crystallography with LCP as a growth and carrier matrix for deliv-
ering microcrystals (LCP-SFX) into an X-ray free-electron laser
(XFEL) beam (Liu et al., 2013; Weierstall et al., 2014; Liu et al.,
2014a), we successfully determined the room-temperature crys-
tal structure of the human AT1R in complex with ZD7155 (AT1R-
ZD7155). Based on the AT1R-ZD7155 structure, we further
performed mutagenesis and docking simulations to reveal bind-
ing modes for clinically used anti-hypertensive drugs targeting
AT1R.
RESULTS
Structure Determination of AT1R-ZD7155 Complex
Using LCP-SFX Method
To facilitate crystallization, a thermostabilized apocytochrome,
b562RIL (BRIL) (Chun et al., 2012), was fused to the amino termi-
nus (N terminus) of the human AT1R. Eleven residues were trun-834 Cell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc.cated from the N-terminal region of AT1R (Met1, Thr7-Asp16), in
order to shorten the flexible N terminus while keeping both the
putative glycosylation site at Asn4 and the disulfide bond site
at Cys18 intact. Forty residues were truncated from the carboxyl
terminus (C terminus) after the cytoplasmic helix VIII (Figure 1A).
The effect of protein engineering on AT1R functionwas evaluated
using radio-ligand binding and calcium mobilization assays, in
which neither the truncations nor BRIL insertion significantly
altered the functional and pharmacological properties of the
receptor for ligand binding and signaling (Figure 1B–1D). With
this engineered AT1R, we obtained micro-crystals (maximum
size 40 3 4 3 4 mm3) in monoolein-based LCP, supplemented
with cholesterol (Figure S1A). These microcrystals diffracted to
only about 4-A˚ resolution at a synchrotron source under cryo-
genic conditions. To improve the resolution and avoid radiation
damage and freezing, we took advantage of a recently devel-
oped LCP-SFX method and collected diffraction data at room
temperature at the Linac Coherent Light Source (LCLS) using
AT1R micro-crystals (average size 10 3 2 3 2 mm
3) grown in sy-
ringes (Figures S1B and S1C). A total of 2,764,739 patterns were
collected by using 65 ml of crystal-loaded LCP, corresponding
to0.35 mg of protein. Of these frames, 457,275 were identified
as crystal hits, corresponding to a hit rate of 17%. Of these crys-
tal hits, 73,130 frames (16%) were successfully indexed and in-
tegrated by CrystFEL (White et al., 2012) to 2.9-A˚ resolution
(Table S1 and Figures S1D–S1F). The structure of the AT1R-
ZD7155 complex was refined to Rwork/Rfree of 22.8%/27.4%.
The final structure includes 289 out of 359 residues in the full-
length human AT1R (Figure 1A), and it has well-defined densities
for most AT1R residues and for the ligand ZD7155.
Overall Architecture of AT1R
AT1R, being the angiotensin II octapeptide receptor, shares
some sequence similarity with other peptide receptors of class
A GPCRs, structures of which are known (sequence alignment
is shown in Figure S2), with the closest homology to the chemo-
kine receptors (e.g., 36% sequence identity with CXCR4) and
opioid receptors (e.g., 33% sequence identity with k-OR) (Wu
et al., 2010; Wu et al., 2012). AT1R exhibits the canonical seven
transmembrane a-helical (7TM) architecture, with an extracel-
lular N terminus, three intracellular loops (ICL1-3), three extracel-
lular loops (ECL1-3), an amphipathic helix VIII and an intracellular
C terminus (Figure 2A). The overall fold of the angiotensin recep-
tor AT1R is most similar to the chemokine and opioid receptors
(Figure 2B), with the lowest root mean square deviation for
80%of AT1R a-carbon atoms (RSMDCa) of about 1.8 A˚ to the no-
ciceptin/orphanin FQ peptide receptor (NOP) (Thompson et al.,
2012). Despite the overall similarity, a number of structural differ-
ences in the transmembrane bundle were observed between
AT1R and other peptide GPCRs (Figures 2C and 2D). For
example, the tilts and extensions of the extracellular ends of he-
lices I, V, VI, and VII are substantially different among these pep-
tide receptors, while at the intracellular side, helices IV and V
adopt themost diverse conformations. The conformations of he-
lices II and III, however, are nearly identical for all these peptide
receptors.
The extracellular part of AT1R consists of the N-terminal
segment, ECL1 (Glu91-Phe96) linking helices II and III, ECL2
Figure 1. AT1R Construct Design and Func-
tional Characterization
(A) Snake plot of the BRIL-AT1R construct used for
crystallization. Residues that occupy the most
conserved positions on each helix in class A
GPCRs (X.50; B&W scheme) are colored in green.
The four cysteine residues that form two disulfide
bonds in the extracellular region are colored in
orange. Three critical residues for ZD7155 binding
are colored in red. All other residues that interact
with ZD7155 are colored in blue. Critical residues/
motifs for AT1R activation are colored in purple.
Truncated residues are shown as light gray, and
residues that do not have sufficient density in the
structure and therefore were not modeled are
shown in dark gray circles.
(B) Saturation binding of the non-peptide antago-
nist 3H-candesartan to the wild-type HA-AT1R,
DBRIL-AT1R, and BRIL-AT1R.
(C) Competition binding of ZD7155 to the wild-type
HA-AT1R, DBRIL-AT1R, and BRIL-AT1R, per-
formed by displacement of 3H-candesartan.
(D) Intracellular calcium responses for the wild-
type HA-AT1R, BRIL-AT1R, and DBRIL-AT1R. The
agonist AngII and the antagonist ZD7155 dose-
response curves for HA-AT1R (circles), BRIL-AT1R
(squares), and DBRIL-AT1R (diamonds) are shown
in closed and open symbols, respectively.
Error bars represent SEM.(His166 to Ile191) linking helices IV and V, and ECL3 (Ile270 to
Cys274) linking helices VI and VII (Figure 1A). Two disulfide
bonds help to shape the extracellular side of AT1R, with
Cys18-Cys274 connecting the N terminus and ECL3, and
Cys101-Cys180 connecting helix III and ECL2, similar to the che-
mokine receptors CXCR4 and CCR5 (Wu et al., 2010; Tan et al.,
2013). Besides engaging in the conserved disulfide bonding,
ECL2 of AT1R exhibits a b-hairpin secondary structure, a com-Cell 161, 833mon motif among peptide GPCRs (Fig-
ure 2E). Intriguingly, ECL2 of AT1R was
found to serve as an epitope for the harm-
ful agonistic autoantibodies in pre-
eclampsia and malignant hypertension
(Unal et al., 2012; Xia and Kellems, 2013).
The intracellular portion of AT1R con-
tains ICL1 (Lys58 to Val62) linking helices
I and II, ICL2 (Val131 to Arg137) linking he-
lices III and IV, ICL3 (Leu222 to Asn235)
linking helices V and VI, and the C-termi-
nal helix VIII. As in many other class A
GPCRs, the conserved D(E)RY motif in
helix III and the NPxxY motif in helix VII
of AT1R, both at the intracellular ends of
transmembrane domain, were proposed
to participate in receptor activation (Oli-
veira et al., 2007). However, the ‘‘ionic
lock’’ salt bridge interaction between
Arg3.50 (superscript indicates residue
number as per the Ballesteros and Wein-
stein, 1995 [B&W] nomenclature) of theD(E)RY motif and Asp/Glu6.30 at the cytoplasmic end of helix VI
is not possible in AT1R, because the human AT1R lacks an acidic
residue at the position 6.30.
The C-terminal helix VIII of AT1R was shown to bind the cal-
cium-regulated effector protein, calmodulin (Thomas et al.,
1999). Integrity of this region is also important for receptor inter-
nalization and coupling to G protein activation and signaling
(Thomas et al., 1995; Sano et al., 1997). In most previously–844, May 7, 2015 ª2015 Elsevier Inc. 835
Figure 2. Overview of AT1R-ZD7155 Architecture and Structural Comparison with Other Peptide GPCRs
(A) Overall AT1R structure is shown as blue cartoon. ZD7155 is shown as spheres with carbon atoms colored green. Membrane boundaries, as defined by the
PPM web server (Lomize et al., 2012), are shown as planes made of gray spheres.
(B–H) superposition of AT1R with chemokine and opioid receptors, chemokine CCR5 receptor, light cyan (PDB ID 4MBS); chemokine CXCR4 receptor, light pink
(PDB ID 3ODU); d-opioid receptor, gray (PDB ID 4N6H); k-opioid receptor, light green (PDB ID 4DJH); NOP receptor, light orange (PDB ID 4EA3), comparing the
whole structure (B), intracellular view (C), extracellular view (D), ECL2 (E), helix VIII (F), and the ligand binding pocket side (G) and top (H) views.
See also Figures S1 and S2 and Table S1.solved GPCR structures, helix VIII runs parallel to the membrane
bilayer, however, in AT1R it angles away from the membrane,
resembling the orientation of this helix in CCR5 (Figure 2F).
Experimentally, the secondary structure of AT1R helix VIII was
observed to be sensitive to hydrophobic environment, thereby
associating with the cytoplasmic side of the cell membrane via836 Cell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc.a high-affinity, anionic phospholipid-specific tethering that
serves to increase the amphipathic helicity of this region (Mozso-
lits et al., 2002). As a separate peptide, helix VIII of AT1R showed
a higher affinity for lipid membranes that contained negatively
charged phospholipids rather than zwitterionic phospholipids
(Kamimori et al., 2005). A high concentration of positively
Figure 3. Interactions of ZD7155 with AT1R
(A) Cross-section view of AT1R highlighting the shape of the ligand binding pocket.
(B) Zoomed-in view of the ligand binding pocket showing all residues within 4 A˚ from the ligand ZD7155, along with the 2mFo-DFc electron density (blue mesh)
contoured at 1 s level. In (A) and (B) ZD7155 is shown as sticks with yellow carbons.
(C) Schematic representation of interactions between AT1R and ZD7155. Hydrogen bonds/salt bridges are shown as red dashed lines. The residues shown by
mutagenesis to be critical for ligand binding are labeled red, those that are important for either peptide or non-peptide ligands binding are labeled in yellow, and
the residues that discriminate between peptide and non-peptide ligands are labeled in purple.
See also Figure S2 and Table S2.charged residues (306-KKFKR-312) in helix VIII of AT1R possibly
defines its orientation and explains its sensitivity to the negatively
charged lipids. Moreover, in AT1R there is no putative palmitoy-
lation site that is present inmanyGPCRs in this region, anchoring
helix VIII to the lipid membrane.
ZD7155 Interactions in AT1R Ligand-Binding Pocket
Small molecule antagonist ZD7155 was modeled into the prom-
inent and well-defined electron density inside the ligand-binding
pocket of AT1R (Figure 3A and 3B), interacting with residues
mainly from helices I, II, III, and VII, as well as ECL2. Side chains
of Arg167ECL2 and Tyr351.39 were found to form ionic and
hydrogen bond interactions with ZD7155. The positively charged
guanidine group of Arg167ECL2 forms an extensive interaction
network with the acidic tetrazole and the naphthyridin-2-one
moieties of ZD7155. Leveraging this information in mutagenesis
studies, we found that mutation of Arg167ECL2 to alanine abol-
ished both the peptide and non-peptide ligands binding to
AT1R (Table S2). However, the Arg167
ECL2Lys mutant showed
only 2- to 3-fold reduced binding affinities for ZD7155, whichcan be explained by the ability of lysine in this position to engage
in salt bridge and hydrogen bond interactions similar to Ar-
g167ECL2, although likely with less optimal interaction geometry.
The tetrazole moiety, or other acidic isostere in the ortho position
of the biphenyl group comprises the most common scaffold
among ARBs, and Arg167ECL2 is a unique residue of AT1R
compared to other structurally similar peptide GPCRs (Fig-
ure S2). This observation suggests that Arg167ECL2 may play
an essential role in determining AT1R ligand-binding affinity
and selectivity. An additional hydrogen bond forms between
Tyr351.39 and the naphthyridin-2-one moiety of ZD7155. Our
data showed that the Tyr351.39Ala mutant abolishes the binding
capabilities of both peptide and non-peptide ligands with AT1R
(Table S2). Tyr1.39 is a well conserved residue in the angiotensin,
chemokine, and opioid receptors (Figure S2). In the CCR5 struc-
ture, for example, Tyr371.39 interacts with its ligand maraviroc
(Tan et al., 2013).
The ZD7155 binding site in AT1R partially overlaps with known
ligand binding sites in the chemokine and opioid receptors (Fig-
ures 2G and 2H). Intriguingly, some of the residues that compriseCell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc. 837
Figure 4. Docking of Different Anti-Hyper-
tensive Drugs in the AT1R Crystal Structure
(A–H) The ARBs are shown as sticks with cyan
carbons. The AT1R residues interacting with li-
gands are labeled and shown as yellow lines, with
the key residues highlighted in red. The hydrogen
bonds are shown as black dashed lines.
See also Table S3.the ligand-binding pockets, including Ile1.35, Phe2.53, Trp2.60, and
Tyr7.43, can be found among these structurally similar peptide
GPCRs (Figure S2). Residues Phe772.53 and Trp842.60 from helix
II of AT1R are conserved in the chemokine receptors CXCR4 and
CCR5 (Wu et al., 2010; Tan et al., 2013). Particularly, Trp842.60 of
AT1R forms p-p interaction with the naphthyridin-2-one moiety
of ZD7155, and mutation of Trp842.60 to alanine abolished both
the peptide and non-peptide ligands binding to AT1R (Figure 3C
and Table S2). Residues Ile311.35 and Tyr2927.43 from helices I
and VII of AT1R are conserved in the opioid receptors k-OR,
d-OR, and NOP. Additionally, residues Val1083.32 and
Leu1123.36, which hydrophobically interact with ZD7155 in the
AT1R ligand-binding pocket, are replaced by Tyr108
3.32 and
Phe1123.36 in CCR5 and form hydrophobic interactions with its
ligand maraviroc. In contrast, the position 3.32 in the aminergic
and opioid receptors is occupied by a conserved aspartic acid
that engages in a salt bridge interaction with ligands. Most of838 Cell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc.the other contacts for ZD7155 binding to
AT1R, however, are mediated by non-
conserved residues, including Tyr872.63,
Thr882.64, Ser1053.29, Ser1093.33,
Ala1634.60, Phe182ECL2, Pro2857.36, and
Ile2887.39 (Figures 3B and 3C and Fig-
ure S2). These residues along with Ar-
g167ECL2 therefore define the unique
shape of the AT1R ligand-binding pocket
and explain the lack of cross-reactivity
between ligands binding to AT1R and
other peptide receptors.
Binding Modes of Different ARBs
toward AT1R
To analyze the common and diverse fea-
tures of the binding modes for different
ARBs in AT1R, we performed energy-
based docking simulations of the clini-
cally used anti-hypertensive ARBs using
the AT1R structure. The docking results
show robust positioning of these com-
pounds in the AT1R ligand-binding pocket
(Figure 4 and Table S3). Although the na-
ture of the interactions with AT1R is
different for each ARB given their distinct
chemical structures, most of these com-
pounds are bound in similar orientations
and engage in interactions with the three
residues critical for ZD7155 binding,
Arg167ECL2, Trp84
2.60, and Tyr351.39 (Fig-ure 5). Residues Phe772.53, Tyr872.63, Ser1053.29, Val1083.32,
Ser1093.33, Leu1123.36, Ala1634.60, Phe182ECL2, Ile2887.39, and
Tyr2927.43 also contribute to the receptor-ligand interactions
and shape the ligand-binding pocket. For example, one of the
common features among these ARBs is a short alkyl tail with
two-four carbons extending into a narrow hydrophobic pocket
formed by Tyr351.39, Phe77
2.53, Val1083.32, Ile2887.39, and
Tyr2927.43 (Figure 5).
Losartan is the first clinically used ARB for the treatment of hy-
pertension. It is, however, a surmountable antagonist with lower
binding affinity to AT1R compared to the later developed ARBs
(Miura et al., 2011). Docking results suggest that Arg167ECL2
forms a salt bridge only with the tetrazole moiety of losartan
but lacks polar interactions with other groups (Figure 4 and Table
S3). Although the derived imidazole moiety of losartan can also
contribute to polar interactions via methanol hydrogen bond to
Cys180ECL2 main chain or via nitrogen interaction with
Figure 5. Common and Distinct Binding Modes of Different ARBs with AT1R
The ARB chemical groups that are engaged in hydrogen bonding/salt bridging with Arg167ECL2 and Tyr351.39 are marked by red and purple dashed circles,
respectively. Pale red and pale purple dotted circles are used for groups with sub-optimal contacts as suggested by docking. The heterocyclic groups forming
p-p contacts with Trp842.60 are surrounded by light-blue dashed circles. The biphenyl-linker groups for hydrophobic interactions are outlined by green dashed
boxes, and the two-four carbons tails, extending into the hydrophobic pocket formed by Tyr351.39, Phe77
2.53, Val1083.32, Ile2887.39, and Tyr2927.43, are outlined
by dark-blue dashed circles. Specific interactions of candesartan and telmisartan with Lys1995.42 are shown by red arrows. Specific interactions between
Tyr92ECL1 and telmisartan, and between Ile2887.39 and eprosartan are highlighted by orange dashed circles.
See also Figure S3.Tyr351.39, distances and angles for hydrogen bonding are sub-
optimal; this may explain the lower binding affinity and sur-
mountable property of losartan at AT1R. An active metabolite
of losartan, EXP3174, is predicted to bind in a similar pose as los-
artan, but instead of interaction with Cys180ECL2, its carboxyl
group could engage in a second salt bridge interaction with Ar-
g167ECL2, similarly to ZD7155 (Table S3). In contrast, candesar-
tan is an insurmountable inverse agonist with a slow dissociation
rate from AT1R (Takezako et al., 2004). The docking results indi-
cate that besides interacting with the tetrazole moiety of cande-
sartan, Arg167ECL2 forms two salt bridges to the carboxylic
group of the benzimidazole moiety (Figure 4 and Table S3).
Moreover, Lys1995.42 is predicted to form an additional salt
bridge with the tetrazole moiety, which can further stabilize can-
desartan binding. Telmisartan lacks the conserved tetrazole
moiety among ARBs. Instead, the carboxylic group of telmisar-
tan is predicted to form salt bridges with both Arg167ECL2 and
Lys1995.42 (Figure 4 and Table S3). Moreover, unlike other
ARBs studied here, two consecutive benzimidazole moieties of
telmisartan extend to Tyr92ECL1, making additional hydrophobic
and p-p contacts, which are likely to contribute to its high po-
tency (Balakumar et al., 2012). This prediction was confirmedby our mutagenesis data, which showed a dramatic decrease
in affinity of telmisartan to the Tyr92 ECL1Ala mutant (Figure S3A).
Eprosartan is the most unique among the ARBs studied here,
lacking both the tetrazole group and one of the two benzene
rings of the biphenyl scaffold. As our docking results suggest,
eprosartan uses its two carboxyl groups to form salt bridges
with Arg167ECL2 (Figure 4 and Table S3). Additionally, the spe-
cific thiophen moiety of eprosartan forms hydrophobic interac-
tions with Pro2857.36 and Ile2887.39 and reaches toward
Met2847.35. Mutation of Met2847.35 to alanine produced minimal
effect, slightly increasing the affinity for eprosartan binding, in
agreement with predicted interactions of this ligand with only
mainchain andCb atoms ofMet284
7.35 (Figure S3B). On the other
hand, mutations Pro2857.36Ala and Ile2887.39Ala induced a
strong decrease in the binding affinity of eprosartan (Figures
S3C and S3D), highlighting essential role of these residues in
eprosartan binding. Finally, both our crystal structure and dock-
ing results suggest that Lys1995.42 retains some conformational
heterogeneity in AT1R. Docking with the flexible side chain of
Lys1995.42 indicates that the amino group of this residue can
reach the acidic moieties of ARBs by forming salt bridges (as in-
teracting with candesartan and telmisartan) or water-mediatedCell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc. 839
Figure 6. Critical Residues for AT1R Activa-
tion
(A) A cluster of aromatic residues (F772.53,
W2536.48 and Y2927.43) is located just below
ZD7155, bridging the ligand binding pocket with a
cluster of polar residues that includes several
highly conserved in class A GPCR residues
(N461.50, D742.50), along with N1113.35 and
N2957.46 forming hydrogen bonds that hold helices
III and VII together.
(B) Superposition of the AT1R structure with the
high-resolution structure of d-OR (PDB ID 4N6H)
reveals a high structural conservation of the puta-
tive sodium-binding site. Sodium ion is shown as
purple ball.interactions, which may explain the reduced ligand-binding ca-
pabilities of Lys1995.42 mutants (Table S2).
Mechanism of AT1R Modulation
Based on previous observations that mutations of either
Asn1113.35 or Asn2957.46 induce constitutive activation of the re-
ceptor, it was proposed that the inactive conformation of AT1R is
stabilized by interactions between Asn1113.35 and Asn2957.46.
Further, it was suggested that binding of AngII to the wild-type
(WT) receptor disrupts the hydrogen bonds between
Asn1113.35 and Asn2957.46, thus allowing Asn2957.46 to interact
with the conserved Asp742.50 (Balakumar and Jagadeesh,
2014; Unal and Karnik, 2014). Indeed, two intramolecular
hydrogen bonds are observed between Asn1113.35 and
Asn2957.46 in the AT1R-ZD7155 structure (Figure 6A). Of partic-
ular interest, Asp742.50, Asn1113.35, and Asn2957.46, together
with two other residues, Trp2536.48 from the WxP motif and
Asn2987.49 from the NPxxY motif, belong to the putative sodium
pocket of AT1R (Katritch et al., 2014) as revealed by super-
position with the sodium site in the high-resolution structure of
d-OR (Figure 6B) (Fenalti et al., 2014). All residues lining this
pocket in AT1R are conserved exactly as in d-OR, except for
Asn2957.46 (Ser in d-OR), which is observed at this position in a
GPCR structure for the first time; therefore, its presence and
the strong hydrogen bond interactions with Asn1113.35 may
impact the sodium binding and functional properties of AT1R.
Moreover, the neighboring residue Phe772.53 from the ligand-
binding pocket of AT1R was also found to be critical for the in-
ter-helical interactions required for AT1R activation (Miura
et al., 2003). Combination of Phe772.53Ala and Asn1113.35Gly
mutations resulted in an almost fully active receptor (Miura
et al., 2008). Thus, multiple structural and functional data sug-
gest that the hydrogen bond network around Asn1113.35 and
Asn2957.46 as revealed in the current structure may play an
essential role in AT1R activation, probably by relaying the confor-
mational changes in the ligand-binding pocket to the cyto-
plasmic domain coupling to the downstream signaling, although
further structural, functional, and biophysical studies are
required to fully understand the mechanism of AT1R modulation.840 Cell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc.DISCUSSION
The angiotensin receptor AT1R is a therapeutic target of
outstanding interest due to its important roles in cardiovascular
pathophysiology. Several AT1R blockers have been developed
and clinically used as anti-hypertensive drugs. Although exten-
sive efforts were taken to delineate the pharmacophores of
AT1R ligands, structure-based drug design was still hindered
by the lack of structural information. By using an XFEL, we suc-
cessfully determined the crystal structure of the human AT1R in
complex with its antagonist ZD7155. Compared to the traditional
X-ray crystallography with cryo-cooled crystals, the LCP-SFX
method yields the room-temperature structure of the AT1R-
ZD7155 complex, which is likely to represent more accurately
the receptor conformations and dynamics in the native cellular
environment. The AT1R-ZD7155 complex structure reveals a va-
riety of key features of AT1R shared with other GPCR family
members, as well as many novel and unique structural charac-
teristics of the angiotensin receptor. Unexpectedly, three AT1R
residues, which have not been previously implicated in binding
small molecule ligands, were found to form critical interactions
with ZD7155; Arg167ECL2 and Tyr351.39 are engaged in ionic
and hydrogen bonds, while Trp842.60 forms extensive p-p inter-
actions with the ligand. The antagonist-bound AT1R structure
was used further for docking of several anti-hypertensive ARBs
into the AT1R ligand-binding pocket, elucidating the structural
basis for AT1R modulation by drugs. Our extensive mutagenesis
experiments revealed that residues Tyr351.39, Trp842.60, Ar-
g167ECL2, and Lys1995.42 are critical for both peptide ([Sar1,
Ile8]-AngII) and non-peptide (candesartan) binding. Residues
Phe182ECL2 and Ile2887.39 discriminate between the peptide
and non-peptide ligand (these mutants do not bind [Sar1, Ile8]-
AngII but bind candesartan). Mutations of Ser1093.33 and
Tyr2927.43 slightly affected non-peptide (candesartan) binding
but not peptide binding (Table S2).
Among the naturally occurring amino acid variations in AT1R,
reported in Uniprot (http://www.uniprot.org/uniprot/P30556),
Ala1634.60Thr, Thr2827.33Met, and Cys2897.40Trp are located
near the binding pocket for ARBs. These variants may directly
alter binding of ARBs and therefore modify the anti-hypertensive
response to treatment with different ARBs in individuals carrying
these variations. In contrast, Leu481.52Val, Leu222ICL3Val, and
Ala2446.39Ser, which are located closer to intracellular ends of
helices, may indirectly influence binding of ARBs or signaling
by AT1R. Finally, Thr336Pro and Pro341His are located in the
C-terminal tail that was not included in the crystalized construct.
These residues, however, are known to affect GPCR kinase-
dependent phosphorylation, an event that is necessary for
b-arrestin recruitment to AT1R.
Of particular interest, the atomic details of ECL2 and the extra-
cellular ligand-binding region, revealed in the current structure,
are expected to guide design of two different types of therapeu-
tic agents targeting AT1R, the anti-hypertensive ARBs exten-
sively interacting with Arg167ECL2 on the ligand-binding pocket
side of ECL2, and the peptide-mimicking antigens against auto-
antibodies, which bind to the extracellular side of ECL2 in pa-
tients with autoimmune disorders, such as preeclampsia and
malignant hypertension (Zhou et al., 2008; Fu et al., 2000). There-
fore, our results provide long anticipated insights into the AT1R
structure-function relationship and pharmacological properties
and demonstrate the potential for using the LCP-SFX method
at XFEL sources to accelerate structural studies of challenging
targets.
EXPERIMENTAL PROCEDURES
Protein Engineering for Structural Studies
The sequence of the human AT1R gene was optimized for insect cell expres-
sion and synthesized by GenScript. A thermostabilized apocytochrome
b562RIL (BRIL) from E. coli (M7W, H102I, R106L) was fused to the N terminus
of the human AT1R, using overlapping PCR. The construct has truncations of
the AT1R residues 1, 7–16, and 320–359. The resulting BRIL-AT1R chimera
sequence was subcloned into amodified pFastBac1 vector (Invitrogen), which
contained a haemagglutinin (HA) signal sequence, a FLAG tag and 10 3 His
tag, followed by a tobacco etch virus (TEV) protease cleavage site, before
the N terminus of the chimera sequence.
Protein Expression and Purification
BRIL-AT1R construct was expressed in Spodoptera frugiperda (Sf9) insect
cells using the Bac-to-Bac baculovirus expression system (Invitrogen). Cells
with a density of 2–3 3 106 cells per ml were infected with baculovirus at
27C, and harvested at 48 hr after infection.
BRIL-AT1R in complex with ZD7155 (Tocris Bioscience) was solubilized
from isolated membranes using 1% (w/v) n-dodecyl-beta-D-maltopyranoside
(DDM, Anatrace) and 0.2% (w/v) cholesterol hemisuccinate (CHS, Sigma-
Aldrich). After purification by metal affinity chromatography BRIL-AT1R/
ZD7155 complex was desalted to remove imidazole using PD MiniTrap G-25
column (GE Healthcare) and then treated overnight with His-tagged TEV pro-
tease to cleave the N-terminal FLAG/His tags from the protein. The cleaved
FLAG/His tags and TEV protease were removed by TALON IMAC resin. The
protein was not treated with PNGase F and therefore remained fully glycosy-
lated. Finally, the purified protein was concentrated to 30 mg/ml with a
100 kDa cutoff concentrator (Vivaspin) and used in crystallization trials. The
protein yield andmonodispersity were tested by analytical size exclusion chro-
matography (aSEC).
Lipidic Cubic Phase Crystallization
BRIL-AT1R in complex with ZD7155 was crystallized in LCP composed of
monoolein supplemented with 10% cholesterol (Caffrey and Cherezov,
2009). LCP crystallization trials were performed using an NT8-LCP crystalliza-
tion robot (Formulatrix). 96-well glass sandwich plates (Marienfeld) were incu-
bated and imaged at 20C using an automatic incubator/imager (RockImager1000, Formulatrix). The crystals grew in the condition of 100mMsodiumcitrate
(pH 5.0–6.0), 300–600 mM NH4H2PO4, 20%–30% (v/v) PEG400 and 2%–8%
(v/v) DMSO. The crystals were harvested using micromounts (MiTeGen) and
flash-frozen in liquid nitrogen for data collection at a synchrotron source.
These crystals diffracted only to about 4-A˚ resolution, even after extensive
optimization of crystallization conditions.
Microcrystals for SFX data collection were prepared in gas-tight syringes
(Hamilton) as described (Liu et al., 2014b), using 100 mM sodium citrate (pH
5.0), 450 mM NH4H2PO4, 28% (v/v) PEG400 and 4% (v/v) DMSO as a precip-
itant. Before loading microcrystals in the LCP injector the excess precipitant
was removed, and 7.9 MAGwas added and mixed with LCP, to absorb the re-
sidual precipitant solution and prevent formation of a crystalline phase due to a
rapid evaporative cooling when injecting LCP into vacuum (Weierstall et al.,
2014).
X-Ray Free Electron Laser Data Collection
Data collection was performed at the Coherent X-ray Imaging (CXI) end station
of the Linac Coherent Light Source (LCLS), SLAC National Accelerator Labo-
ratory, using XFEL pulses of 36 fs duration focused to a size of 1.5 3 1.5 mm2
by Kirkpatrick-Baez mirrors. A photon energy of 7.9 keV, an average pulse en-
ergy of 2.7 mJ and a transmission level of 16% resulted in a maximum dose of
75 MGy at the sample.
Microcrystals dispersed in LCPwere delivered into the interaction region us-
ing an LCP injector (Weierstall et al., 2014) with a 50 mm diameter nozzle at a
flow rate of 170 nl per minute. Diffraction patterns were collected on a Cor-
nell-SLAC Pixel array detector (CSPAD - version 1.5) (Hart et al., 2012) at a
rate of 120 Hz.
With a total sample volume of 65 ml, a total of 2,764,739 diffraction frames
were collected within 6.4 hr. Initial frames were corrected and filtered using
the software package Cheetah (Barty et al., 2014). A crystal ‘‘hit’’ was defined
as an image containing aminimum of 15 diffraction peaks with a signal to noise
ratio above 4. A total of 457,275 positive ‘‘hits’’ were further processed using
the CrystFEL software suite (version 0.5.3) (White et al., 2012). The detector
geometry was refined using an automated algorithm designed to match found
and predicted peaks to sub-pixel accuracy. By further refinement of parame-
ters (peak detection, prediction, and integration), a total of 73,130 images were
indexed, integrated, and merged into a final dataset. To reduce noise and out-
liers and thus improve data quality we have applied two data rejection criteria:
(1) per pattern resolution cutoff, and (2) rejection of patterns based on a
Pearson correlation coefficient threshold, as described in the Extended Exper-
imental Procedures. A resolution cutoff was estimated to be 2.9 A˚ using a com-
bination of CC* (Karplus and Diederichs, 2012) and other parameters (Figures
S1D–S1F). The final dataset had overall Rsplit = 9.8%, and CC* = 0.872 in the
highest resolution shell.
Structure Determination
The structure was solved bymolecular replacement with Phaser (McCoy et al.,
2007) using an automated script described in the Extended Experimental
Procedures.
Refinement and model completion were performed by repetitive cycling be-
tween Refmac5 (Murshudov et al., 1997) and autoBUSTER (Bricogne et al.,
2009), followed by manual examination and rebuilding of the refined coordi-
nates in Coot (Emsley et al., 2010). Data collection and refinement statistics
are shown in Table S1.
Docking of ARBs into AT1R Ligand-Binding Pocket
Representative ARBs were docked into the AT1R crystal structure using an en-
ergy-based docking protocol implemented in ICM molecular modeling soft-
ware suite (Molsoft). Molecular models of compounds were generated from
two-dimensional representations and their 3D geometry was optimized using
MMFF-94 force field (Halgren, 1995). Molecular docking employed biased
probability Monte Carlo (BPMC) optimization of the ligand internal coordinates
in the grid potentials of the receptor (Totrov and Abagyan, 1997). To ensure
convergence of the docking procedure, at least five independent docking
runs were performed for each ligand starting from a random conformation.
The results of individual docking runs for each ligand were considered consis-
tent if at least three of the five docking runs produced similar ligandCell 161, 833–844, May 7, 2015 ª2015 Elsevier Inc. 841
conformations (RMSD < 2.0 A˚) and Binding Score < 20.0 kJ/mol. The unbi-
ased docking procedure did not use distance restraints or any other a priori
derived information for the ligand-receptor interactions.
Ligand Binding Assays
Ligand binding was analyzed using total membranes prepared from COS-1
cells transiently expressing HA-AT1R (wild-type), DBRIL-AT1R (crystallized
construct without BRIL), and BRIL-AT1R (crystallized construct) constructs.
Single mutants were constructed by a PCR-based site-directed mutagenesis
strategy as previously described (Unal et al., 2010). Protein concentration was
determined by Bio-Rad Protein Assay (Bio-Rad). For both saturation and
competition binding assays, 10 mg of homogenous cell membrane was used
per well.
Saturation binding assays with 3H-candesartan were performed under equi-
librium conditions, with 3H-candesartan (Amersham Pharmacia Biotech) con-
centrations ranging between 0.125 and 12 nM (specific activity, 16 Ci/mmol) as
duplicates in 96-well plates for 1 hr at room temperature. Nonspecific binding
was measured in the presence of 10 mM candesartan (gift from AstraZeneca).
The binding kinetics were analyzed by nonlinear curve-fitting program Graph-
Pad Prism 5, which yielded the mean ± SD for the Kd and Bmax values.
Competition binding assays were performed under equilibrium conditions,
with 2 nM 3H-candesartan and various concentrations of the ZD7155 ranging
between 0.04 and 1,000 nM. The binding kinetics were analyzed by nonlinear
curve-fitting program GraphPad Prism 5, which yielded the mean ± SD for the
IC50 values.
Signaling Assays in Whole Cells
Calcium levels inside COS-1 cells transiently expressing different AT1R con-
structs were measured using a Fluorescent Imaging Plate Reader (FLIPR) Cal-
cium 5 assay kit (Molecular Devices). For the antagonist dose-response, the
cells were first treatedwith different concentrations of ZD7155 for 1 hr followed
by stimulation with 100 nM AngII. The EC50 values for AngII dose response
were 0.2, 2, and 12 nM for HA-AT1R, DBRIL-AT1R, and BRIL-AT1R, respec-
tively. The IC50 values for ZD7155 to inhibit AngII response were between 3
to 4 nM for all constructs. The curves from a representative experiment
whereinmeasurements aremade in triplicate are shown asmean ±SEM. Addi-
tional information is available in the Extended Experimental Procedures.
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